Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 3, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 5, 2026
CFOTax withholding
Context
Classification
tax withholding
Code F — shares delivered to pay exercise price or tax liability
Planned / mechanical clue
Tax mechanics (code F)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-092155
Filed / recorded
Mar 5, 2026, 6:20 AM UTC
Added to OQRO
Oct 6, 2026, 7:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CORCEPT THERAPEUTICS INC
Issuer CIK
1088856
Ticker
CORT
Reporting person
Atabak Mokari
Relationship
Officer
Officer title
Chief Financial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 3, 2026
Transaction code
F
Shares / units
96
Price per share
$35.97
Acquired / disposed
Disposed (D)
Shares owned after
15,257
Ownership form
Direct
Amendment
No
Footnotes from the filing
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
The closing price on March 2, 2026 was used to calculate the withholding obligation.
Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.